Clinical Trials in Minneapolis

Showing 3721-3740 of 14,456 trials

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

NCT06594445

This is a Phase I dose finding study of GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing refractory/relapsed myeloid malignancies in adults ≥ 18 years of age who are not a candidate for potentially curative therapy, including hematopoietic stem cell transplantation, and are refractory to, intolerant of, or ineligible for therapy options that are known to provide clinical benefit. The hypothesis is GTB-3650 TriKE will induce natural killer (NK) cell function by targeting malignant cells, as well as, CD33+ myeloid derived suppressor cells (MDSC) which contribute to a tumor induced immunosuppression. Because CD16 is the most potent activating receptor on NK cells, this single agent may induce a targeted antiCD33+ tumor response

Myeloid MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes

Masonic Cancer Center, University of Minnesota45 participantsStarted Nov 2024

Minneapolis, Minnesota, United States

COMPLETEDPhase 277 miles

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

NCT04963231

The purpose of this study was to evaluate the safety and efficacy of once daily subcutaneous (SC) administration of setmelanotide in participants with obesity and specific gene variants in the MC4R pathway.

Genetic Obesity

Rhythm Pharmaceuticals, Inc.164 participantsStarted Nov 2021

Scottsdale, Arizona, United States • Suwanee, Georgia, United States • Worcester, Massachusetts, United States +33 more locations

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Find Trials by Condition in Minneapolis

A Study to Investigate LYL845 in Adults With Solid Tumors

A Study to Investigate LYL797 in Adults With Solid Tumors

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Vaginal Ecosystem and Network in the United States Study

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

Abbott Vascular Medical Device Registry

Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

DISSECT-N Post Market Data Collection Registry

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules